T1	intervention 0 18	Lanreotide Autogel
T2	condition 29 40	lymphorrhea
T4	outcome-Measure 468 554	lymphorrhea volume (ml) in the axillary drain during the first four postoperative days
T11	total-participants 868 871	148
T12	total-participants 922 925	145
T13	control-participants 1022 1024	73
T14	control 1047 1054	placebo
T15	intervention-participants 1059 1061	72
T16	outcome 1151 1186	reduction of the lymphorrhea volume
T17	outcome 1378 1432	no significant difference for the secondary end points
T18	outcome 1502 1520	lymphorrhea volume
T19	iv-cont-median 1219 1225	292 ml
T20	cv-cont-median 1284 1290	337 ml
T3	outcome-Measure 590 633	number of days until axillary drain removal
T5	outcome-Measure 635 664	hospital stay duration (days)
T6	outcome-Measure 666 689	lymphorrhea volume (ml)
T7	outcome-Measure 717 788	number of cases with seroma aspiration and number of seroma aspirations
T8	outcome-Measure 790 809	evaluation of wound
T9	outcome-Measure 811 819	arm pain
T10	outcome-Measure 824 832	mobility
